UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000052279
Receipt number R000059676
Scientific Title A Study on the Effect of Plant Extract on Postprandial Serum Uric Acid -A Randomized, Double-blind, Placebo-controlled, Cross-over Study-
Date of disclosure of the study information 2023/09/23
Last modified on 2024/08/01 19:09:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study on the Effect of Plant Extract on Postprandial Serum Uric Acid
-A Randomized, Double-blind, Placebo-controlled, Cross-over Study-

Acronym

A Study on the Effect of Plant Extract on Postprandial Serum Uric Acid

Scientific Title

A Study on the Effect of Plant Extract on Postprandial Serum Uric Acid
-A Randomized, Double-blind, Placebo-controlled, Cross-over Study-

Scientific Title:Acronym

A Study on the Effect of Plant Extract on Postprandial Serum Uric Acid

Region

Japan


Condition

Condition

No

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm the effect of plant extract on postprandial serum uric acid

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Serum uric acid and change in uric acid

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Active food, single ingestion. Wash out. Placebo food, single ingestion.

Interventions/Control_2

Placebo food, single ingestion. Wash out. Active food, single ingestion.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male

Key inclusion criteria

(1)Healthy males aged 20 to 64 years-old.
(2)Subjects whose serum uric acid levels are 7.9 mg/dL or less by the screening tests, however, more than half of all subjects have a serum uric acid level of 7.0 mg/dL or less.
(3)Subjects who can make self-judgment and are voluntarily giving written informed consent.

Key exclusion criteria

(1)Subjects who are judged hyperuricemia in need of treatment and are under treatment.
(2)Subjects who contract and/or are under treatment serious diseases (eg, liver disease, kidney disease, digestive disease, heart disease, respiratory disease, endocrine disease and/or metabolic disease).
(3)Subjects with a disease that may have an influence on this study currently under treatment.
(4)Subjects who have a surgical history of digestive disease affecting digestion and absorption.
(5)Subjects who have declared an allergic reaction to test foods, or loading foods.
(6)Subjects who can't stop using medicines, supplements and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) affecting serum uric acid during test periods.
(7)Subjects who drink excessive alcohol, or who can't stop drinking from 2 days before each measurement.
(8)Subjects who are planning to participate and/or had participated in other clinical studies that may have an influence on this study.
(9)Subjects who are judged as unsuitable for the current study by the investigator for other reasons.

Target sample size

25


Research contact person

Name of lead principal investigator

1st name Saeko
Middle name
Last name Isaka

Organization

TOYO SHINYAKU Co., Ltd.

Division name

Clinical and analytical research center

Zip code

841-0005

Address

7-28 Yayoigaoka, Tosu-Shi, Saga, Japan

TEL

0942-81-3555

Email

isakas@toyoshinyaku.co.jp


Public contact

Name of contact person

1st name Nobutaka
Middle name
Last name Kusaba

Organization

TOYO SHINYAKU Co., Ltd.

Division name

Clinical and analytical research center

Zip code

841-0005

Address

7-28 Yayoigaoka, Tosu-Shi, Saga, Japan

TEL

0942-81-3555

Homepage URL


Email

gakujutsu@toyoshinyaku.co.jp


Sponsor or person

Institute

TOYO SHINYAKU Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

TOYO SHINYAKU Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Miura Clinic, Medical Corporation Kanonkai IRB

Address

9F Higashitenma building, 1-7-17 Higashitenma, Kita-ku, Osaka, Osaka, Japan

Tel

06-6135-5200

Email

mterashima@miura-cl.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 09 Month 23 Day


Related information

URL releasing protocol

https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000059676

Publication of results

Published


Result

URL related to results and publications

https://www.medicalonline.jp/search?query=%A5%BF%A1%BC%A5%DF%A5%CA%A5%EA%A5%A2%A5%D9%A5%EA%A5%EA%A5%

Number of participants that the trial has enrolled

25

Results

Statistically significant difference was confirmed in the primary outcome.

Results date posted

2024 Year 08 Month 01 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Males aged 20 to 64 years old

Participant flow

Enrolled(n=25)
Completed(n=24)
Analyzed(n=22)

Adverse events

No adverse events were observed that be related to test food.

Outcome measures

Serum uric acid and change in uric acid

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2023 Year 09 Month 12 Day

Date of IRB

2023 Year 09 Month 21 Day

Anticipated trial start date

2023 Year 09 Month 25 Day

Last follow-up date

2023 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 09 Month 22 Day

Last modified on

2024 Year 08 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059676